Japan’s pharmaceutical industry doesn’t have even a single candidate for new antibiotics to counter multidrug-resistant superbugs such as some types of Acinetobacter and E. coli bacteria, according to an expert reporting the situation to the government.
Shuhei Fujimoto, a professor at Tokai University’s Department of Bacteriology and Bacterial Infection, said he alerted the Health, Labor and Welfare Ministry’s study group on superbugs to the lack of new antibiotics indispensable to treat people infected with such bacteria.
"Although the battle with multidrug-resistant bacteria has long been buttressed by developments of new antibiotics, we are in a critical situation at present," he said.
Low profitability of antibiotics appears to be a factor behind pharmaceutical manufacturers’ reluctance to make developmental efforts for new antibiotics, he said.
Read the rest of the story: No antibiotic candidates emerge to stem superbugs.